Intellia Therapeutics, Inc.
NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.29
Price-4.97%
-$0.59
1Y
Price
Market Cap
$1.212b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-385.3%
EBITDA Margin-371.3%
Net Profit Margin-425.7%
Free Cash Flow MarginRevenue
$45.569m
+45.0%
1y CAGR+24.1%
3y CAGR+7.3%
5y CAGREarnings
-$525.914m
-0.9%
1y CAGR-29.3%
3y CAGR-48.7%
5y CAGREPS
-$5.26
+1.1%
1y CAGR-19.3%
3y CAGR-30.3%
5y CAGRBook Value
$779.919m
$986.163m
Assets$206.244m
Liabilities$119.253m
DebtDebt to Assets
12.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$381.155m
-2.4%
1y CAGR-23.8%
3y CAGR-104.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company